{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:31Z","timestamp":1786991131402,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112225","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:47:22Z","timestamp":1715885242000},"page":"112225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program"],"prefix":"10.1016","volume":"134","author":[{"given":"Leopoldina","family":"Falc\u00f3n Lincheta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaimarelis","family":"Saumell N\u00e1poles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaine R.","family":"Gray Lovio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina M.","family":"Viqueira Fuentesfr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"P\u00e9rez Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Batista Romagoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleida","family":"Urquiza Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mantec\u00f3n Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heber A.","family":"Bautista Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damarys","family":"Fern\u00e1ndez de Armas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldenida S.","family":"Mart\u00ednez Matute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakelin","family":"Le\u00f3n Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana K.","family":"Oramas Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaneisy","family":"Marrero Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymara","family":"Fernandez Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Valls Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9164-0238","authenticated-orcid":false,"given":"Patricia","family":"Lorenzo-Luaces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Valenzuela Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-4826","authenticated-orcid":false,"given":"Ernesto","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-3116","authenticated-orcid":false,"given":"Patricia","family":"Hern\u00e1ndez-Casa\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112225_b0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7748\/ns.25.35.47.s47","article-title":"An overview and update of psoriasis","volume":"25","author":"Green","year":"2011","journal-title":"Nurs. Stand."},{"key":"10.1016\/j.intimp.2024.112225_b0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and management of psoriasis and associated comorbidiTy (IMPACT) project team, Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0015","first-page":"12","article-title":"Descriptive study with 200 patients","volume":"41","author":"Trujillo","year":"2002","journal-title":"Rev. Cubana Med."},{"key":"10.1016\/j.intimp.2024.112225_b0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"Oliveira Mde","year":"2015","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0025","doi-asserted-by":"crossref","first-page":"e880201","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of psoriasis and comorbid diseases: a narrative review","volume":"13","author":"Bu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0030","doi-asserted-by":"crossref","first-page":"e743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"16","author":"Damiani","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.112225_b0035","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of Psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112225_b0040","doi-asserted-by":"crossref","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.intimp.2024.112225_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13555-022-00846-3","article-title":"Elevating the standard of care for patients with psoriasis: 'calls to action' from epicensus, a multistakeholder pan-european initiative","volume":"13","author":"Koren","year":"2023","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2024.112225_b0050","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/cells9122589","article-title":"Soluble CD5 and CD6: lymphocytic class I scavenger receptors as immunotherapeutic agents","volume":"9","author":"Velasco-de Andr\u00e9s","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.intimp.2024.112225_b0055","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3389\/fimmu.2018.02994","article-title":"CD6, a rheostat-type signalosome that tunes T Cell activation","volume":"9","author":"Gon\u00e7alves","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.822290","article-title":"Gene variation at immunomodulatory and cell adhesion molecules loci impacts primary sj\u00f6gren's syndrome","volume":"9","author":"Casad\u00f3-Llombart","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.112225_b0065","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjy179","article-title":"Critical role of CD6highCD4+ T cells in driving Th1\/Th17 Cell immune responses and mucosal inflammation in IBD","volume":"13","author":"Ma","year":"2019","journal-title":"J. Crohns Colitis."},{"key":"10.1016\/j.intimp.2024.112225_b0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40259-013-0027-4","article-title":"CD6 as a therapeutic target in autoimmune diseases: successes and challenges","volume":"27","author":"Pinto","year":"2013","journal-title":"BioDrugs."},{"key":"10.1016\/j.intimp.2024.112225_b0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/1389450117666160201105934","article-title":"The link between CD6 and autoimmunity: genetic and cellular associations","volume":"17","author":"Kofler","year":"2016","journal-title":"Curr. Drug Targets."},{"key":"10.1016\/j.intimp.2024.112225_b0080","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cmi.2017.119","article-title":"Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis","volume":"15","author":"Consuegra-Fern\u00e1ndez","year":"2018","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0085","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/1389450117666160201114308","article-title":"Therapeutic targeting of CD6 in autoimmune diseases: a review of cuban clinical studies with the antibodies IOR-T1 and Itolizumab","volume":"17","author":"Hern\u00e1ndez","year":"2016","journal-title":"Curr. Drug Targets."},{"key":"10.1016\/j.intimp.2024.112225_b0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14712598.2020.1776254","article-title":"Anti-CD6 mAbs for the treatment of psoriasis","volume":"20","author":"Dogra","year":"2020","journal-title":"Expert Opin Biol. Ther."},{"key":"10.1016\/j.intimp.2024.112225_b0095","doi-asserted-by":"crossref","first-page":"96.13","DOI":"10.4049\/jimmunol.184.Supp.96.13","article-title":"Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis - results from a randomized phase II trial","volume":"184","author":"Anand","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2014.01.897","article-title":"Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study","volume":"71","author":"Krupashankar","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0105","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/nbt1213-1062b","article-title":"Biocon\u2019s first-in-class anti-CD6 mAb reaches the market","volume":"31","author":"Jayaraman","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2024.112225_b0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.rinim.2012.11.001","article-title":"A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis","volume":"2","author":"Rodriguez","year":"2012","journal-title":"Results Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0115","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10067-015-2988-9","article-title":"Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study","volume":"35","author":"Chopra","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.112225_b0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cei.13061","article-title":"The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial","volume":"191","author":"Rodr\u00edguez","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/cti2.1218","article-title":"Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab","volume":"9","author":"Caballero","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14712598.2021.1905794","article-title":"A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19","volume":"21","author":"Kumar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2024.112225_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.112225_b0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatology."},{"key":"10.1016\/j.intimp.2024.112225_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/247553031016a00205","article-title":"How long does the benefit of biologics last? an update on time to relapse and potential for rebound of biologic agents for psoriasis","volume":"16","author":"Kamaria","year":"2010","journal-title":"Psoriasis Forum."},{"key":"10.1016\/j.intimp.2024.112225_b0150","doi-asserted-by":"crossref","first-page":"e0180088","DOI":"10.1371\/journal.pone.0180088","article-title":"T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab","volume":"12","author":"Bughani","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.intimp.2024.112225_b0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2249.2010.04235.x","article-title":"CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction","volume":"162","author":"Nair","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2024.112225_b0160","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4161\/mabs.28376","article-title":"Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab","volume":"6","author":"Aira","year":"2014","journal-title":"Mabs."},{"key":"10.1016\/j.intimp.2024.112225_b0165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.mcna.2009.08.003","article-title":"Evaluation and management of psoriasis: an internist\u2019s guide","volume":"93","author":"Levine","year":"2009","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.intimp.2024.112225_b0170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1468-3083.2001.00191.x","article-title":"Prevalence of psoriasis in Spain (Epiderma Project: phase I)","volume":"15","author":"Ferr\u00e1ndiz","year":"2001","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2024.112225_b0180","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000109357","article-title":"Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a norwegian population survey among adults","volume":"216","author":"B\u00f8","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.intimp.2024.112225_b0190","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"10.1016\/j.intimp.2024.112225_b0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","article-title":"Trends in incidence of adult-onset psoriasis over three decades: a population-based study","volume":"60","author":"Icen","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0205","first-page":"112","article-title":"Epidemiology of psoriasis in malaysia: a hospital based study","volume":"65","author":"Sinniah","year":"2010","journal-title":"Med. J. Malaysia."},{"key":"10.1016\/j.intimp.2024.112225_b0210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003\u20132012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.intimp.2024.112225_b0215","first-page":"874","article-title":"Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis","volume":"21","author":"Feldman","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.intimp.2024.112225_b0220","doi-asserted-by":"crossref","unstructured":"A.B. Kimball, D.Jr. Robinson, Y. Wu, C. Guzzo, N. Yeilding, et al., Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002, Dermatology. 217 (2008) 27-37. https:\/\/doi.org\/10.1159\/000121333.","DOI":"10.1159\/000121333"},{"key":"10.1016\/j.intimp.2024.112225_b0225","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","article-title":"Medical comorbidity associated with psoriasis in adults: a population-based study","volume":"165","author":"Yang","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0230","first-page":"WD01-WD03","article-title":"Safety and efficacy of itolizumab in the treatment of psoriasis: a case series of 20 patients","volume":"10","author":"Parthasaradhi","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.intimp.2024.112225_b0235","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/idoj.IDOJ_330_16","article-title":"A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis","volume":"8","author":"Parthasaradhi","year":"2017","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.intimp.2024.112225_b0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0245","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/bjd.13518","article-title":"Association between psoriasis and asthma: a population-based retrospective cohort analysis","volume":"172","author":"Fang","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0250","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1093\/hmg\/ddt317","article-title":"A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis","volume":"22","author":"Weidinger","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2024.112225_b0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jphs.2018.12.006","article-title":"Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: a network meta-analysis","volume":"139","author":"Xu","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2024.112225_b0260","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol. Ther. (heidelb)"},{"key":"10.1016\/j.intimp.2024.112225_b0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2475530321999087","article-title":"Speed of psoriasis treatment response for biologic agents: a review OF PHAse III clinical trials","volume":"6","author":"Johnson","year":"2021","journal-title":"J. Psoriasis Psoriatic Arthritis."},{"key":"10.1016\/j.intimp.2024.112225_b0270","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0275","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ced.12509","article-title":"Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience","volume":"40","author":"Budamakuntla","year":"2015","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0280","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40257-018-0408-z","article-title":"Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2\/-3 Randomized Trials","volume":"20","author":"McMichael","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2024.112225_b0295","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0300","first-page":"S403","article-title":"Contemporary management of moderate to severe plaque psoriasis","volume":"23","author":"Wu","year":"2017","journal-title":"Am. J. Manag. Care."},{"key":"10.1016\/j.intimp.2024.112225_b0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13555-022-00843-6","article-title":"Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry","volume":"13","author":"Yu","year":"2023","journal-title":"Dermatol. Ther. (heidelb)"},{"key":"10.1016\/j.intimp.2024.112225_b0310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1346-8138.15146","article-title":"Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan","volume":"47","author":"Kishimoto","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2024.112225_b0315","doi-asserted-by":"crossref","unstructured":"S. Dogra, D. S. K., L. Budamakuntla, C.R. Srinivas, U. Khopkar, et al., Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study, J. Am. Acad. Dermatol. 73 (2015) 331-3.e1. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.040.","DOI":"10.1016\/j.jaad.2015.03.040"},{"key":"10.1016\/j.intimp.2024.112225_b0320","first-page":"19","article-title":"Spotlight on itolizumab in the treatment of psoriasis \u2013 current perspectives from India","volume":"9","author":"Budamakuntla","year":"2019","journal-title":"Psoriasis (auckl)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T09:04:37Z","timestamp":1735290277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":64,"alternative-id":["S1567576924007446"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112225","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112225"}}